Global Micro Invasive Glaucoma Surgery Devices Market Size By Type (Implants, Blink-assisted Devices), By Application (Hospital, Ophthalmology Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market was valued at USD 792 million in 2023 and is projected to reach USD 1.96 billion by 2031, expanding at a CAGR of 12.1% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increasing prevalence of glaucoma, the growing geriatric population, rising preference for minimally invasive surgeries, and advancements in ophthalmic surgical devices. MIGS devices are increasingly favored due to their safer profile compared to traditional glaucoma surgeries and their ability to reduce intraocular pressure (IOP) with fewer complications, shorter recovery times, and better patient compliance.

Drivers:

1. Rising Global Burden of Glaucoma:

Glaucoma is one of the leading causes of irreversible blindness worldwide. The aging population and greater awareness have significantly increased the diagnosis rate, fueling the demand for effective and less invasive treatment options such as MIGS devices.

2. Shift Toward Minimally Invasive Procedures:

Healthcare providers and patients are favoring procedures that offer shorter hospital stays, quicker recovery, and fewer post-operative complications. MIGS devices align with this preference, driving their adoption globally.

3. Technological Advancements in Ophthalmic Surgery:

Continuous innovations, including devices with improved fluidic control and compatibility with combined cataract surgeries, are enhancing surgical precision and outcomes, making MIGS devices more attractive to ophthalmologists and patients alike.

Restraints:

1. High Cost and Limited Reimbursement Policies:

Despite their clinical advantages, the high cost of MIGS devices and the limited reimbursement coverage in many regions pose barriers to widespread adoption, especially in cost-sensitive markets.

2. Surgeon Training and Adoption:

The effectiveness of MIGS devices depends on the skill and experience of the ophthalmic surgeon. A lack of trained professionals and slower adoption rates in developing regions restrict the market’s growth potential.

Opportunity:

1. Expanding Access in Emerging Economies:

As healthcare infrastructure improves and awareness of glaucoma grows in emerging markets like India, China, and Brazil, there is significant potential for market expansion driven by increased procedural volume and favorable healthcare reforms.

2. Integration with Cataract Surgeries:

The increasing integration of MIGS procedures with cataract surgery offers dual benefits—restoring vision and controlling intraocular pressure—making it a compelling value proposition that can drive future growth.

Market by System Type Insights:

Based on system type, the Stent Devices segment accounted for the largest share in 2023, owing to their proven efficacy in enhancing aqueous humor outflow and reducing intraocular pressure. These devices are typically used in combination with cataract surgery, contributing to their widespread clinical adoption. The Trabecular Meshwork Devices segment is expected to register the fastest growth during the forecast period due to ongoing innovations in bypass technologies and expanding indications.

Market by End-use Insights:

Hospitals and Ophthalmology Clinics collectively dominate the market, with ophthalmology clinics leading due to the increasing number of outpatient glaucoma surgeries performed in ambulatory settings. These facilities benefit from faster patient turnover, lower costs, and specialist care, further fueling market growth. Academic and research institutes are also contributing through clinical trials and device validation studies.

Market by Regional Insights:

North America led the global MIGS devices market in 2023, driven by favorable reimbursement scenarios, robust healthcare infrastructure, and early adoption of novel surgical techniques. Asia-Pacific is poised to witness the highest CAGR during the forecast period, fueled by rising glaucoma awareness, increasing elderly population, and growing investments in ophthalmic care infrastructure across India, China, and Southeast Asia.

Competitive Scenario:

Key players in the Global Micro Invasive Glaucoma Surgery Devices Market include:

Glaukos Corporation

Alcon Inc.

Santen Pharmaceutical Co., Ltd.

Ivantis Inc. (part of Alcon)

Sight Sciences Inc.

iStar Medical SA

New World Medical, Inc.

These companies are focusing on regulatory approvals, clinical trials, product innovation, and mergers to strengthen their positions. For instance:

In 2023, Glaukos Corporation received expanded FDA approval for its iStent infinite, targeting a broader patient base with open-angle glaucoma.

Sight Sciences Inc. launched the second-generation OMNI Surgical System in 2024, aimed at enhancing surgeon ergonomics and procedural outcomes.

Scope of Work – Global Micro Invasive Glaucoma Surgery Devices Market

Report Metric Details

Market Size (2023) USD 792 million

Projected Market Size (2031) USD 1.96 billion

CAGR (2023–2031) 12.1%

Market Segments By System Type (Stents, Trabecular Meshwork Devices), By End-use (Hospitals, Ophthalmology Clinics)

Growth Drivers Increasing glaucoma prevalence, preference for minimally invasive surgeries, and integration with cataract procedures

Opportunities Emerging markets expansion, technological innovations, reimbursement improvements

Key Market Developments:

2023: Glaukos Corporation secured FDA approval for iStent infinite, expanding treatment options for patients with moderate-to-severe open-angle glaucoma.

2024: Alcon integrated Ivantis' Hydrus Microstent with its cataract surgery platform to improve surgical workflow and outcomes.

2025: Sight Sciences launched enhanced versions of the OMNI Surgical System, focusing on improved usability for outpatient clinics.

FAQs:

1) What is the current market size of the Global Micro Invasive Glaucoma Surgery Devices Market?

The market was valued at USD 792 million in 2023.

2) What is the major growth driver of the Global Micro Invasive Glaucoma Surgery Devices Market?

The major driver is the rising prevalence of glaucoma and increasing preference for safer, minimally invasive surgical alternatives.

3) Which is the largest region during the forecast period in the Global Micro Invasive Glaucoma Surgery Devices Market?

North America is expected to maintain its lead due to high adoption rates and supportive reimbursement policies.

4) Which segment accounted for the largest market share in the Global Micro Invasive Glaucoma Surgery Devices Market?

The Stent Devices segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Micro Invasive Glaucoma Surgery Devices Market?

Key players include Glaukos Corporation, Alcon Inc., Santen Pharmaceutical, Ivantis Inc., Sight Sciences Inc., and iStar Medical SA.

Would you like this content exported to a Word or PDF document?